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INTRODUCTION
The  hemodynamic  responses  to  laryngoscopy  and  endotracheal 
intubation have been recognized since 1951. Though these pressor responses 
have been observed frequently they have been interpreted differently by many 
authors.  The induction of anaesthesia, laryngoscopy, endotracheal intubation 
and surgical stimulation often evoke cardiovascular responses characterized by 
alterations  in  systemic  blood  pressure,  heart  rate  and  cardiac  rhythm.  The 
response following laryngoscopy and intubation peaks at 1-2 min and returns to 
baseline within 5-10 mins.
These  sympathoadrenergic  responses  are  probably  of  little  clinical 
consequence  in  healthy  patients.  Complications  like  left  ventricular  failure, 
myocardial ischemia and cerebral haemorrhage have been attributed to sudden 
rise  in  systemic  arterial  blood  pressure  and  increase  in  heart  rate.   These 
complications  are  more  likely  to  occur  in  patients  with  pre  existing 
hypertension,  coronary  heart  disease,  cerebral  vascular  disease,  intracranial 
pathology and hyperactive airways. In such cases, reflex circulatory responses 
such as increase in heart rate, systemic arterial blood pressure and disturbances 
in cardiac rhythm need to be suppressed.
Prof.  Ward  and  King (1960)  in  their  combined  study  documented 
myocardial  ischemic  changes  due  to  reflex  sympathoadrenal  response 
immediately following laryngoscopy and endotracheal intubation with a mean 
increase in systemic pressure of 40mmHg even in normotensive patients.
Prys Roberts et al (1971) showed an exaggerated form of this response 
in hypertensives. Anti hypertensives modify the response but do not inhibit it 
completely.
The  hemodynamic  responses  during  laryngocopy  and  endotracheal 
intubation should be abolished to balance the myocardial oxygen supply and 
demand which is a key note in the safe conduct of Anaesthesia.
Attempts  to  reduce  these  untoward  cardiovascular  responses  during 
laryngoscopy and endotracheal intubation lead to the trial of various systemic 
as well as topical agents. 
The  present  concept  of  a  definitive  sympathetic  overactivity  during 
laryngeal  intubation  clearly  shows  that  a  more  protection  against  vagal 
overactivity and the use of anticholinergic drugs alone maynot be sufficient. 
Those techniques  which require   prior  laryngoscopy to administer  the  local 
anaesthetic solution are likely to be of limited value.  The common strategies 
adapted are narcotics, vasodilators,  Beta blockers, calcium channel blockers, 
lidocaine and other sympatholytics. 
The  inclusion  of  a  rapid  onset,  short  duration,  water  soluble,  cardio 
selective β blocker, Esmolol to the armamentarium of the anaesthesiologist to 
control periods of intense sympathetic stimulation, namely laryngoscopy and 
endotracheal intubation adds on to the safety of anaesthesia.
Fentanyl,  a  potent  narcotic  can  also  attenuate  pressor  response  by 
maintaining  proper  depth  of  anaesthesia.  Analgesic  effect  of  fentanyl 
suppresses the nociceptive stimulation caused by the intubation procedure.  The 
centrally  mediated  decrease  in  sympathetic  tone  observed  by  Lambie  et  al 
(1974), might partly be involved in pressor response attenuation.
In our study, we have compared the efficacy of bolus administration of 
IV  esmolol  and  IV  fentanyl  to  suppress  the  pressor  response  during 
laryngoscopy and endotracheal intubation.  This study was undertaken in the 
Department of Anaesthesiology, Government Rajaji Hospital, Madurai Medical 
College, Madurai.
AIM OF THE STUDY
This study was done to compare the efficacy of bolus administration of 
IV  esmolol  2mg/kg  and IV  fentanyl  3  mcg/kg in  attenuating  the 
cardiovascular stress responses accompanying laryngoscopy and endotracheal 
intubation  by  measuring  heart  rate,  systolic  blood  pressure,  diastolic  blood 
pressure and mean arterial pressure with control group.
NERVE SUPPLY OF LARYNX
The nerve supply of the larynx is from Vagus via superior and Recurrent 
laryngeal nerve branches.  Superior laryngeal nerve passes deep to both internal 
and external  carotid  arteries  and  there  divides  into  a  small  external  branch 
which supplies cricothyroid muscle and a large internal branch which supplies 
the  interior  of  larynx  as  far  down  as  the  vocal  cords  after  piercing  the 
thyrohyoid membrane.
The Recurrent laryngeal nerve on the right side leaves the Vagus as the 
latter crosses right subclavian artery, it then loops under the artery and ascends 
to the larynx in the groove between oesophagus and trachea.  On the left side 
the same originates from the vagus as it crosses the aortic arch, then it passes 
under the arch to reach the groove between oesophagus and trachea.  Once it 
reaches the neck the left nerve has the same relationship as on the right side. 
The  recurrent  laryngeal  nerve  provides  the  motor  supply  to  the  intrinsic 
muscles of the larynx except the cricothyroid.  It  also has a sensory branch 
which supplies laryngeal mucosa inferior to the vocal cords.
NERVE SUPPLY OF TRACHEA 
The muscle  fibres  of  the  trachea,  including the  trachealis  muscle,  are 
innervated by the recurrent laryngeal nerves which also carry sensory fibres 
from the mucous membrane.  Sympathetic nerve fibres are derived mainly from 
the middle cervical ganglion and have connections with the recurrent laryngeal 
nerves.
PHYSIOLOGIC AND PATHOPHYSIOLOGIC RESPONSES TO DIRECT 
LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION
Intubation  of  trachea  alters  respiratory  and  cardiovascular  physiology 
both via, reflex responses and by the physical presence of endotracheal tube. 
Although the reflex responses are generally of shorter  duration and of little 
consequences  in  the  majority  of  patients,  they  may  produce  profound 
disturbance  in  patients  with  underlying  abnormalities  such  as  hypertension, 
coronary artery disease, reactive airways and intracranial neuro pathology.  
Cardiovascular Responses :
The  cardiovascular  responses  to  laryngoscopy  and  intubation  are 
bradycardia,  tachycardia  and hypertension.   They are  mediated  by  both  the 
sympathetic and parasympathetic nervous system.  Bradycardia is often seen in 
infants and small children during laryngoscopy and intubation.  Although only 
rarely seen in adults, this reflex is mediated by an increase in vagal tone at the 
sinoatrial node and is virtually a monosynaptic response to a noxious stimulus 
in the airway.
The more common response to endotracheal intubation is hypertension 
and tachycardia mediated by sympathetic efferents  via the Cardioaccelerator 
nerves and sympathetic chain ganglia.  The polysynaptic nature of the pathways 
from the  vagal  and  Glossopharyngeal  afferents  to  the  sympathetic  nervous 
system  via  the  brain  stem  and  spinal  cord  results  in  a  diffuse  autonomic 
response which includes widespread release of nor-epinephrine from adrenergic 
nerve terminals and secretion of epinephrine from the adrenal medulla.  Some 
of  the  hypertensive  response  to  endotracheal  intubation  also  results  from 
activation of the renin angiotensin system, with the release of renin from the 
renal juxtaglomerular apparatus,  an end organ innervated by beta adrenergic 
nerve terminals.
Central Nervous System :
In addition to activation of the autonomic nervous system endo tracheal 
intubation  also  stimulates  CNS  activity  as  evidenced  by  increasing 
electroencephalographic activity, cerebral  metabolic oxygen requirement and 
cerebral blood flow.
Respiratory system :
The effect  of  endotracheal  intubation on the  pulmonary vasculature  is 
probably  less  well  understood  than  the  responses  elicited  in  the  systemic 
circulation.
AIRWAY-EFFECTS OF ENDOTRACHEAL INTUBATION
1. Upper Airway Reflex : Laryngospasm
Afferent  pathyway  for  laryngospasm  and  cardiovascular  responses  to 
endotracheal  intubation  are  mediated  by  the  Glossopharyngeal  nerve  when 
stimuli occur superior to the anterior surface of the epiglottis and by the vagus 
N when stimuli occur from the level of posterior epiglottis down into the lower 
airway.
Laryngospasm is  a  monosynaptic  reflex  primarily  elicited  under  light 
general anesthesia when vagally innervated nerve endings in the upper airway 
are stimulated and conscious respiratory efforts cannot override the reflex.
2.  Dead Space :
Normal  extrathoracic  anatomical  dead  space  of  75  ml  which  on 
intubation is reduced by 60 ml.
3.  Upper Airway Resistance :
Endotracheal  tube  causes  a  mechanical  burden  for  a  spontaneously 
breathing patient  in  the  form of  a  fixed upper  airway resistance  because  it 
decreases airway caliber and increases resistance to breathing.
4.  Lower Airway Resistance :
Bronchospasm  can  occur.  Reflex  increase  in  airway  resistance  may 
occur.   Receptors  in  the  larynx and  upper  trachea  may cause  large  airway 
constriction  distal  to  the  tube  which  in  turn  may  extend  to  the  smaller 
peripheral  airways.   Rapid  changes  in  airway  caliber  following  airway 
instrumentation are thought to result largely from parasympathetic activation of 
airway  smooth  muscle.   Cholinergically  induced  broncho  constriction  is  a 
normal airway response to intubation in anaesthetized patients.
5. Endotracheal tube Resistance and Exhalation :
Endotracheal tube may limit expiratory flow so that full exhalation does 
not occur.
6.  Functional residual capacity (FRC) :
Presence of endotracheal tube tends to reduce the FRC
7.  Cough :
Efficiency is reduced whenever an endotracheal tube is in place.
8. When the upper airway is bypassed following intubation the gases must 
be warmed and humidified.
Intubation and Cardiovascular Diseases :
The most common adverse cardiovascular problem related to intubation 
is myocardial ischemia in patients with coronary  insufficiency.  Because two 
of  the  major  determinants  of  O2 consumption namely  heart  rate  and blood 
pressure are markedly increased during intubation.
The integrity of cerebral and aortic aneurysms is largely a function of 
transmural pressure.  Accordingly a sudden increase in blood pressure can lead 
to rupture of the vessels and sudden deterioration of the patients condition.
Intubation in neuropathologic disorders can cause dangerous increase in 
intracranial pressure and transient impairment of cerebral perfusion.
Before the advent of neuromuscular blocking drugs, intubation was only 
performed under such deep levels of anaesthesia that there was relatively little 
cardiovascular responses generated.
METHODS TO ATTENUATE CIRCULATORY RESPONSES DURING 
LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION 
The sympathoadrenal responses should be abolished as maintenance of 
delicate  balance  between  myocardial  oxygen supply  and  demand forms the 
keynote in the safe conduct of anaesthesia.
Various methods tried by various workers are
I.  Deepening of General Anaesthesia :
Inhalational anaesthetic agents – The dose of volatile agent required to 
block the cardiovascular response to endotracheal intubation.  This deep level 
of  anaesthesia  achieved  by  inhalational  agents  results  in  profound 
cardiovascular  depression  prior  to  endotracheal  intubation.   Various  agents 
used are Halothane, Isoflurane and Seroflurane.
II  Lignocaine :
a) Lignocaine gargle for Oropharyngeal anaesthesia
b) Aerosol for intratracheal anaesthesia
c) Topical spray for vocal cords
d) Regional nerve blocks – superior laryngeal nerve, glossopharyngeal 
nerve
e) Intravenous administration.
Topical  anaesthesia  of  upper  airway  has  proved  to  be  less  effective  than 
systemic administration of lignocaine.
Mechanism :
1. By increasing the depth of general anaesthesia
2. Potentiation of effects of nitrous oxide anaesthesia and reduction of 
MAC for halothane by 10-28%
3. Direct myocardial depression
4. Peripheral vasodilatation
5. Anti arrhythmic properties
6. Suppression of cough reflex
III   Vasodilators :
Hydralazine
Sodium Nitroprusside
Nitroglycerin
IV  Narcotics :
Fentanyl
Alfentanil
Sufentanil
Morphine
Pethidine
Fentanyl is most commonly used narcotic agent.  It is a
a) Potent analgesic
b) Has short duration of action
c) Doesnot increase intracranial tension during controlled   ventilation
d) Minimal circulatory changes
Mechanism :
1. Analgesic effect of Fentanyl suppresses the nociceptive stimulation 
caused by the intubation procedure.
2. The  centrally  mediated  decrease  in  sympathetic  tone  observed  by 
Lambie  et  al,  (1974)  when  investigating  the  mechanism  of 
hypotension induced by fentanyl in dogs, might partly be involved.
3. Activation of vagal tone by fentanyl was also observed.
V – Adrenergic Blockers :
Long acting :  Metoprolol, phentolamine,
Propranolol, labetalol
Short acting : Esmolol
Of these, Esmolol is most commonly used agent because of its ultra 
short action.
It reduces resting heart rate, systolic blood pressure, Ejection fraction and 
cardiac index but it maintains coronary perfusion pressure.
VI  Calcium channel blockers
Nifedipine, 
Nicardipine
Diltiazem
Verapamil 
Nicardipine has got superior action
VII  Alpha 2 agonist
Clonidine – suppresses the increase in sympathetic activity evoked by the 
intubation.
VIII – Midazolam :
Sedation and anxiolytic
IX -  Magnesium Sulphate :
Sedation and anxiolytic
PHYSIOLOGY OF BETA – RECEPTORS
Autonomic  nervous  system  regulate  body’s  ongoing  physiological 
function automatically by a dual function.
First by maintaining an internal environment, and secondly by preparing 
and enabling the body to undertake extra efforts in situations of threat to the 
body’s well being.
Parasympathetic cholinergic system is a restorative system.  Sympathetic 
adrenergic is primarily stimulatory preparing the body for fight or flight.
In cardiovascular system sympathetic and parasympathetic system are in 
constant  opposition,  and  the  state  of  the  system depends  on  which  system 
predominates.
AHLQUIST  (1960)  characterized  sympathetic  stimulation  as  being 
predominantly mediated through alpha or beta receptor effects.   Lands et  al 
(1961) observed that beta receptor activity is due to two forms, beta 1 and beta 
2 receptor stimulation and is responsible for the effect of sympathetic nervous 
activation on the heart, smooth muscle relaxation in vascular and respiratory 
systems, renin release, tissue lipolysis and glycogenolysis.
Beta  1  receptor  is  primarily  involved  in  cardiac  effects.   In  special 
circumstances like chronic cardiac failure beta 2 receptors may also mediate 
cardiac activity.
In congestive cardiac failure beta 1 density decreases without changes in 
beta 2 receptor accounting for higher inotropic response by isoproterenol.
Beta  agonist  posses  higher  affinity  for  coupled  activator  forms of  the 
receptor,  whereas beta antagonists have affinity for both active and inactive 
forms with no cellular activity.  In addition antagonists maintain the receptors 
in a relatively inactive form so that considerably more agonists are required to 
unbalance the equilibrium.
BETA RECEPTOR ANTAGONISTS
      Most  of  the  currently  available   β–blocking  drugs  are 
propranolamines.  The commercial formulation is a racemic mixture, in which 
the “L” form is the active ingredient.
INDICATIONS
They are of use in
a) Cardiac  arrhythmias  which  are  principally  due  to  sympathetic 
stimulation  as  in  phaeochromocytoma,  myocardial  infarction  and 
arrhythmias associated with anaesthesia.
b) Ischemic heart disease – improves Oxygen supply – demand ratio.
c) Hypertensive cardiovascular disease – associated with a high plasma 
renin activity.
d) Thyrotoxicosis
e) Obstructive cardiomyopathy
f) Phaeochromocytoma,  Hereditory  Tremors,  Anxiety  neurosis, 
Schizophrenia, Drug addiction and Migraine
Adverse Reactions :
a. Bronchoconstriction
b. Cardiac Failure
c. Peripheral vascular insufficiency
d. Hypoglycemia and
e. Drug interaction (e.g.,) antidiabetics.
THE BETA ADRENERGIC BLOCKING DRUGS
Drugs Potency 
propra 
nolol=1
Beta 
selective
Intrinsic 
sympath
o 
mimetic
Membrane 
Stabilizing 
activity
Lipid 
solubility
Hepatic 
meta 
bolism
Propranolol 1 - - + High 99
Timolol 6 - - - Moderate 80
Nadolol 0.8 - - - Low 27
Metoprolol 1 + + - - Moderate 97
Atenolol 1 + + - - Low < 10
Pindolol 6 - + ++ + Mod/Low 60
Oxprenolol 1 - + + + Moderate 97
Acebutolol 0.3 + + + High 80
Labetalol 0.3 - - - Mod/High 90+
Esmolol 0.5 + + + - - Low 0-10
PHARMACOLOGY OF ESMOLOL
In 1982, ZAROSLINSKI  described the concept of an ultrashort acting β 
-adrenergic  blocker.   From this  work esmolol  which is  a  cardioselective  β-
blocker  that  has  an  extremely  short  duration  of  action  was  subsequently 
identified and characterized.
Chemistry :
      Esmolol is chemically Methyl p- [2-hydroxy -3 (isopropylamino) propoxy] 
hydrocinnamate hydrochloride, a molecular structure characteristic of second 
generation β -blockers.  Esmolol contains an ester in the para position of phenyl 
ring.  The presence and location of this ester is of fundamental importance in 
the determination of Esmolol’s cardioselectivity as well as its ultrashort action.
Esmolol  has  the  empirical  formula  C16 H26 NO4 C1 and  a  molecular 
weight of 331.8.  It has one asymmetric centre and exists as an enantiomeric 
pair.
Esmolol hydrochloride is a white to off-white crystalline powder.  It is a 
relatively  hydrophilic  compound  which  is  very  soluble  in  water  and  freely 
soluble in alcohol.
Clinical Pharmacology :
           Esmolol  hydrochloride  is  a  β1–selective  (cardioselective) 
aderenergic receptor blocking agent with rapid onset, a very short duration of 
action and no significant intrinsic sympathomimetic or membrane stabilizing 
activity  at  therapeutic  dose.   It  inhibits  the  β1 receptors  located  chiefly  in 
cardiac muscle, but their preferential effect is not absolute and at higher doses it 
begin to  inhibit   β2-  receptors  located chiefly in the  bronchial  and vascular 
musculature.  Esmolol is 43 fold more potent at β receptors in atria (β1) than in 
Trachea (β2).  Blockade of vascular β–receptors required a dose several – fold 
greater than that required for cardiac  β–blockade. Esmolol does not have any 
effect on peripheral vascular resistance.
Pharmacokinetics and Metabolism :
Esmolol is rapidly metabolished by hydrolysis of ester linkage, chiefly by 
esterase in the cytosol of red blood cells and not by plasma cholinesterase or 
red  cell  membrane  acetylcholinesterase.   Total  body  clearance  in  man was 
found to be 20 L /  kg /  hr  which is greater  than cardiac output.   Thus the 
metabolism  of  Esmolol  is  not  limited  by  the  rate  of  blood  flow  to  the 
metabolising tissues such as the liver and kidney. It has a rapid distribution 
half-life of about 2 minutes and an elimination half-life of about 9 minutes.
After an appropriate loading dose, steady state blood levels of Esmolol 
are obtained within 5 minutes.   Steady state  is  obtained within 30 minutes, 
without  a  loading  dose.   Steady  state  blood  levels  are  maintained  during 
infusion but fall rapidly after termination of the infusion (20 minutes).  Since it 
has  a  short  half-life,  blood  levels  can  be  rapidly  altered  by  increasing  or 
decreasing the infusion rate.
Metabolism of  Esmolol  results  in the formation of an acid metabolite 
(ASL-8123)  phenyl  propionic  acid  and methanol.   The  acid  metabolite  has 
1/1500th the activity of Esmolol and its blood levels do not correspond to the 
level of  β – blockade. Acid metabolite has an elimination half life of about 3.7 
hrs and is excreted in the urine with a clearance approximately equal to the 
glomerular  filtration  rate.  Elimination  of  acid  metabolite  is  significantly 
decreased in patients with renal disease with the elimination half-life increased 
to ten-fold that of normal.   Esmolol is unaffected by plasma cholinesterase. 
For full enzymatic activity, the Esmolol esterase in RBC cytosol requires a heat 
– labile high molecular weight plasma component.  The enzyme is not inhibited 
to any significant degree of cholinesterase inhibitor such as physostigmine or 
echothiophate,  but  is  totally  inhibited  by  sodium  fluoride.  No  metabolic 
interactions  has  been  observed between  Esmolol  and other  ester  containing 
molecules of clinical relevance. It does not modify the magnitude or duration of 
neuromuscular blockade in response to succinylcholine (Richard J.Gorzynski). 
Esmolol is 55% bound to human plasma protein while acid metabolite is only 
10% bound.
In human electrophysiological studies Esmolol produced effects typical 
of  a  β –  blocker  ;  decrease  in  heart  rate,  increase  in  sinus  cycle  length, 
prolongation of sinus node recovery time.
1. Esmolol  produces reduction in heart  rate,  systolic  blood pressure,  rate 
pressure product and right ventricular ejection fraction and cardiac index at rest 
and  during  exercise,  similar  in  magnitude  to  propranolol,  but  produces 
significantly  lower  fall  in  systolic  blood  pressure  ;  Esmolol  also  produces 
small, clinically insignificant increase in left ventricular end-diastolic pressure 
and pulmonary capillary wedge pressure.  30 minutes after discontinuation of 
infusion all the haemodynamic parameters return to pretreatment levels.
2. Cardioselectivity of Esmolol was demonstrated by infusion of Esmolol in 
asthmatic patients which produced no significant increase in specific airway 
resistance  compared  to  placebo.   Unlike  Esmolol,  propranolol  produces 
significant bronchospasm requiring bronchodilator therapy.  Esmolol shows no 
adverse pulmonary effects in patients with COPD.
3. Esmolol  is  very  effective  in  the  management  of  supraventricular 
tachycardia, atrial fibrillation and atrial flutter.
There is significant decrease in blood pressure compared to propranolol 
but was rapidly reversible with decreased infusion rates or on discontinuation. 
Hypotension was less frequent in those patients receiving concomitant digoxin.
Drug Interactions :
Catecholamine  depleting  drugs  (eg.  Reserpine)  may  have  an  additive 
effect  when  given  with  Esmolol.  So  patients  should  be  observed  for 
hypotension or marked bradycardia.
Esmolol concentrations were higher when given with warfarin but this is 
of no clinical importance.  When given with digoxin blood levels of digoxin 
were high and when given with morphine blood levels of Esmolol were high.
Indications :
For rapid control of ventricular rate as in atrial flutter or fibrillation.  For 
short term control of ventricular rate when short acting agents are desirable as 
in (SVT, unstable angina, myocardial infarction) and to control perioperative 
tachycardia.
Contraindications :
In patients with sinus bradycardia,  heart  block,  cardiogenic shock and 
overt cardiac failure, diabetics and end stage renal disease.
Adverse Reactions :
CVS –  Symptomatic  hypotension  occurs  in  12%  of  patients. 
Asymptomatic hypotension in 25% of patients.  Hypotension gets resolved on 
discontinuation  of  treatment.   Very  rarely  bradycardia,  chest  pain,  syncope, 
sinus pause and asystole occur all reversible with discontinuation of treatment.
CNS : Dizziness, Headache, agitation and fatigue.
RS : Bronchospasm, nasal congestion – relatively less.
GIT :      Nausea, vomiting, constipation, Diarrhoea, Drymouth.
Skin :
Inflammation,  and  induration  at  the  site  of  infusion,  Oedema,  skin 
discolouration, thrombophlebitis and local skin necrosis.
Acute Toxicity :
Accidental massive overdose when it occurs is due to an error in dilution. 
It can cause hypotension, bronchospasm, drowsiness, bradycardia and loss of 
consciousness.   These are resolved within ten minutes of discontinuation or 
with administration of a pressor agent.
Compatibility :
Compatible  with  commonly  used  intravenous  fluids  except  sodium 
bicarbonate injection.
Preparations Available :
100 mg - 10 ml vial
2.5 g - 10 ml amp
Dosage :
To  attenuate  the  sympathoadrenal  response  during  laryngoscopy  and 
intubation, the dosage is 1.5 mg/kg as bolus or as an infusion at the rate of 500 
mcg/kg/minute for 2 minute as loading dose followed by a maintenance dose of 
100 mcg/kg/minute.
To  initiate  treatment  of  a  patient  with  supraventricular  tachycardia,  a 
loading dose of 500 mcg/kg/minute for 1 minute followed by  maintenance 
infusion of 50 mcg/kg/minute for 4 minutes.  If an adequate therapeutic effect 
is not observed within 5 minutes, the same loading dose can be repeated and 
followed with a maintenance infusion increased to 100 mcg/kg/min, therapeutic 
plasma level being 400-1200 nano gm/ml.  The time to 100% recovery is 30 
minutes.
PHARMACOLOGY OF FENTANYL
Fentanyl  is  a  synthetic  narcotic  agonist  that  is  related  to  the  phenyl 
piperidines. Acts at  μ receptors as an agonist.  Fentanyl when compared to 
morphine-a prototype opioid as an analgesic is 80-100 times more potent, has a 
more rapid onset and shorter duration of action than morphine.
Structure :
Fentanyl  is  chemically  identified  as  N  -1(1-phenethyl  –  4  piperidyl 
propionanilide citrate).  
The empirical formula is C22  H28 N2O C6 H8 O7.
Availability :
Ampoules – 2 ml containing 100 micrograms (Fendrop, Fenstrong)
10 ml ampoules containing 50 μg per ml.
Lollipop – for paediatric use
Patches – Transdermally delivering 75-100 μg/hr
Routes of Administration :
Fentanyl is the only opioid available for various forms of administration.
• Intramuscular
• Intravenous
• Neuraxial – Spinal, Epidural administration for intra and post operative 
analgesia.
• Transdermal  –  applied before  the  induction of  anaesthesia  and left  in 
place for 24 hours. Reduces the amount of parental opioid requirement or 
post operative analgesia.
• Transmucosal  –  To  decrease  anxiety  and  to  facilitate  induction  of 
anaesthesia especially in children.
Pharmacodynamics :
Acute effects :
CNS
Analgesia Cough suppressant
Sedation Miosis
Hypnosis Nausea, vomiting
Euphoria Skeletal muscle rigidity
Respiratory depressant
CVS Others
Vasodilatation Smooth muscle spasm
Bradycardia  Histamine release
Hypotension Decreases the stress response
Chronic effects :
Tolerance
Physical dependance
Mechanism of Action :
I – CNS effects :
1.  Analgesia and Mood effects :
a.  The processing of pain information is inhibited by a direct spinal effect of 
dorsal horn.
b. Rostral  transmission  of  pain  signals  is  decreased  by  activation  of 
descending inhibitory pathways in the brainstem.
c. Emotional  response  to  pain  is  altered  by  opioid  actions  in  the  limbic 
cortex.
d. Act at receptors located peripherally on sensory neuron.
2.  Respiratory Depression :
Direct effect on respiratory centre in the medulla.
3.  Antitussive – Direct effect on cough centre in medulla
4. Miosis – Stimulation of Edinger – Westphal nucleus of IIIrd nerve.
5.Nausea,  vomiting :  Stimulation  of  chemoreceptor  trigger  zone  complex, 
interaction of dopaminergic, cholinergic or serotonergic mechanism.
6. Muscle rigidity :  By acting at the receptor in the striatum, increases the 
rate  of  striatal  dopaminergic  biosynthesis  and  inhibits  the  release  of  the 
inhibitory neurotransmitter GABA.
II -   Cardiovascular System :
a) Bradycardia : Stimulation of central vagal nucleus
b) Peripheral vasodilatation :  Depression of vasomotor centre in medulla
c) Decreased  central  sympathetic  tone  :   Raising  the  arrhythmogenic 
threshold
d) Hypotension : Especially in patients with elevated sympathetic tone like 
hypovolemia, cardiac failure.
III – Neuro endocrine effects :
Fentanyl  and  its  congener  are  more  effective  in  modifying  hormone 
responses to surgery.
Analgesic  effect  of  fentanyl  suppresses  the  nociceptive  stimulation 
caused by intubation procedure.
IV - Tolerance :
Acute tolerance or tachyphylaxis, 
Chronic tolerance, 
Cross tolerance to other opioid agonist,
Develops most rapidly to depressant effects of opioids.
Pharmacokinetics :
Fentanyl administered IV has a more rapid onset and shorter duration of 
action.  The greater potency and more rapid onset of action reflects the greater 
lipid solubility which facilitates its passage across the blood-brain barrier.
The short duration of action of a single dose of fentanyl reflects its rapid 
redistribution to inactive tissue sites such as fat and skeletal muscles, with an 
associated decrease in the plasma concentration of the drug.  The lungs also 
serve as  a  large,  inactive  storage site,  with an estimated 75% of  the  initial 
fentanyl  dose undergoing first pass pulmonary uptake.
Fentanyl is extensively metabolished by dealkylation, hydroxylation and 
amide  hydrolysis  to  inactive  metabolites,  including  norfentanyl  and 
desproprionylnorfentanyl that are excreted in bile and urine.
The pharmacokinetics of fentanyl can be described as three compartment 
model with a distribution time of 1.7 minutes, redistribution of 13 minutes and 
a terminal elimination half time of 219 minutes.  The volume of distribution is 
4 L / kg.
Onset time and Duration of action :
Route of 
administration
Onset of time 
(minutes)
Duration of action 
(hours)
IM 7 – 8 1 – 2
IV Immediate 0.5 – 1
Clinical uses :
• As a narcotic analgesic during premedication, induction and maintenance of 
anaesthesia and in post operative period as need arises.
• To blunt the circulatory response to direct laryngoscopy for intubation and 
as an adjuvant to inhaled anaesthetics to prevent sudden changes in the level 
of anaesthesia due to surgical stimulation.
• As an anaesthetic agent with oxygen, in high risk patients such as those 
undergoing  open  heart  surgery  or  certain  complicated  neurological  or 
orthopaedic procedures.
• As a neuroleptic anaesthetic agent with neuroleptic agents like droperidol.
• Neuraxially either alone or in combination with local anaesthetic to improve 
the quality of the blockade intraoperatively or for post operative analgesia.
Dosage :
IM : 50 – 100 μg (1-2 μg/kg)
IV : Low dose of fentanyl 1-2 μg / kg -  To provide analgesia
2  -  20  μg  /  kg  IV  -  Administered  as  an  adjuvant  to  inhaled 
anesthetics  in  an  attempt  to  blunt  circulatory  responses  to  direct 
laryngoscopy for intubation of the trachea or sudden changes in the level 
of surgical stimulation.
50 – 150 μg /  kg IV   (large  doses  of  fentanyl)  To produce surgical 
anaesthesia
Intrathecal : 10-50 μg (0.25 – 0.5 μg / kg)
Epidural : Bolus dosing – 1 μg / kg
Continuous infusion after the bolus -  30-100 μg / hr
Oral transmucosal fentanyl : 15-20 μg / kg
Transdermal fentanyl Patch :  75-100 μg/hr
Adverse effects :
Respiratory depression Dizziness
Rigidity Blurred vision
Laryngospasm Emesis
Apnoea Diaphoresis
Hypotension
Bradycardia
Drug interactions :
1. Nitrous oxide potentiates cardiovascular depression when given with 
higher doses of fentanyl.
2. Even relatively  small  doses  of  diazepam may cause  cardiovascular 
depression when administered with high dose of fentanyl.
3. Fentanyl and tranquilizer can lead to hypotension
4. Fentanyl and MAO inhibitors can lead to hypotension.
REVIEW OF LITERATURE
Though laryngoscopy and intubation were performed with ease in yester years, 
the Anaesthesiologists had to struggle to combat or subdue the circulatory or cardio 
vascular  effects  of  the  said  procedure  in  patients  with  compromised  circulatory 
system.
RIED&BRACE  (1940)  postulated  that  reflex  circulatory  responses  to 
laryngeal instrumentation were mediated through the vagus nerve and they named it 
as “Vaso Vagal Reflex”.
KING  et  al  (1951) used  deep  Ether  anaesthesia  to  abolish  the  reflex 
circulatory response to tracheal intubation.
KING  and  his  associates  (1960)  believed  the  reflex  mechanisms  to  be 
essentially  non-specific  in  character.  They  stated  that  the  impulses  initiating  the 
reflex  arc  are  probably  carried  over  the  vagus,  while  the  effector  system is  less 
clearly  defined  and  may  be  due  to  decreased  parasympathetic  or  increased 
sympathetic adrenal activity.
WYCOFF  C.C.(1960) in  his  study  stated  that  topical  anaesthesia  of  the 
pharynx along with Superior laryngeal nerve blocks, reduced the increase in mean 
arterial pressure after intubation.
FORBES and DALLY (1970) observed that laryngoscopy and endo tracheal 
intubation  is  immediately  associated  with  an  average  increase  in  mean  arterial 
pressure  of  25mm of  Hg in  all  22  normotensive  patients.  These  responses  were 
interpreted as due to reflex sympathetic adrenal stimulation.
PRY ROBERT et al (1971)  found that the increases in heart rate and blood 
pressure are much more exaggerated in hypertensive patients.
FOEX et al  (1971) observed
i. Inotropic Failure
ii. Ischemic arrhythmias and
iii. Cerebrovascular accidents.
In  patients  with  uncontrolled  hypertension  who  came  up  for  emergency 
surgery and associated substantial increase in heart rate and blood pressure following 
laryngoscopy and endotracheal intubation which lasted for several minutes.
DENLINGER  J.K  and  ELLISON  N.E.  (1974)  have  used  intratracheal 
lignocaine spray which causes a 50% reduction in the hypertensive response.
VICTORIA FARIA BALNC and NORMAND A.G. (1974) in their article of 
“Complications of Tracheal  Intubation” have classified the neurogenic or  reflexly 
mediated complication into three different categories.
i. Laryngo Vagal Reflexes- Which give rise to spasm of the glottis, bronchospasm, 
apnoea, bradycardia, cardiac dysrhythmias and arterial hypotension. The mere 
presence  of  the  tracheal  tube  seems  to  be  the  most  common  cause  of 
bronchospasm in anaesthetized asthmatic patients.
ii. Laryngo  Sympathetic  Reflexes-  which  include  tachycardia  tachyarrhythmias, 
acute  arterial  hypertension  as  frequent   complication.  The  hypertensive 
hyperdynamic state during laryngoscopy may be related in some cases to an 
increased noradrenaline fraction of the total catecholamines.
iii. Laryngo Spinal Reflexes- which include coughing, vomiting and bucking
LUNN  (1979),  BENNETT  and  STANLEY  (1980)  have  observed  that 
induction dose of fentanyl 150 mcg/kg or even as little as 4mcg/kg given 10 min 
after nitrousoxide – oxygen induction abolished the increase in blood pressure and 
heart rate.
J.CURRAN,  M.CROWLEY (1980)  have  studied  the  use  of  Droperidol  an 
alpha blocker to attenuate the pressor response. Droperidol administration was found 
to be associated with an undesirably low mean arterial pressure for a short period in a 
proportion of patients.
ELLIOFF  et  al  (1980)  by  echo  cardiographic  study  found  that  there  was 
substantial  worsening  of  left  ventricular  wall  function  –  akinesia,  dyskinesia  or 
hypokinesia following laryngoscopy and endotracheal intubation.
DONAL E.MARTIN (1982)  have  also  proved the  efficacy  of  a  low dose 
fentanyl along with an induction dose of thiopentone, but in these series, it was also 
found that the incidence and occurrence of tachycardia was not prevented. 
V.M.KAVTTO  (1982)  studied  attenuation  of  the  circulatory  response  to 
laryngoscopy  and  intubation  -  fentanyl  6mcg  /kg  completely  abolished  these 
responses.
T.E BLACK, B.KAY AND T.E.J SLEACY (1984) compared alfentanil with 
fentanyl in reducing the haemodynamic responses to laryngoscopy and intubation 
and found that no increase were noted in groups receiving 30 mcg/kg alfentanil or 5 
mcg/kg of fentanyl and alfentanil effect appears to have a shorter duration than that 
of fentanyl.
B.KAY, T.E.J. HAECY and P.M. BOLDER (1985) compared fentanyl and 
nalbuphine in blocking the circulatory response to tracheal intubation and found that 
nalbuphine attenuated the mean pressure response to these maneuvers but had no 
effect  in  the  accompanying  tachycardia  and  fentanyl  5  mcg/kg  prevents  these 
responses however at the cost of significant decrease in both blood pressure and heart 
rate and increase in respiratory depression.
DONAL R.MILLER and RAYMOND J.MARTINEAN (1989) used bolus 
dose  of  esmolol  for  treating  hypertension,  tachycardia  and  myocardial  ischemia 
intraoperatively.
PARNASS  SM,  ROTHENBERG  DM,  KERCHBERGER  JP  and 
IVANKOVICH AD (1990) demonstrated that single bolus dose of esmolol blunted 
tachycardia and hypertensive response to laryngoscopy and endo tracheal intubation.
STEVEN  M.  HELFMAN,  MARTIN  I  GOLD,  EVERTARD  A,  DE 
LESSER and CLAIRE A. HERRINGTON (1991) observed that esmolol provides 
consistent and reliable protection from increase in both heart rate and systolic blood 
pressure  during  and  after  intubation.  Where  as  lignocaine  and  fentanyl  failed  to 
protect  against  increases  in  heart  rate  but  provided protection against  increase  in 
systolic blood pressure equivalent to that provided by esmolol.
D.R.MILLER  and  R.J.  MARTENEAN  (1991)  concluded  that  esmolol 
1.5mg/kg  is  safe  and  effective  in  controlling  cardiovascular  responses  during 
anaesthetic induction.
HELFMAN SM, GOLD MI, DELISSER EA, HERRINGTON CA in 1991 
demonstrated that only esmolol provided consistent and reliable protection against 
increase in both heart rate and systolic blood pressure accompanying laryngoscopy 
and intubation.
FENQ CK, CHAN KH, LOKN, ORCH, LECTY in 1996,  observed that 
only esmolol could reliablly offer protection against increase in both heart rate and 
systolic blood pressure, low dose fentanyl (3mcg/kg) prevented hypertension but not 
tachycardia  and  2mg/kg  lidocaine  has  no  effect  to  blunt  adverse  haemodynamic 
response during layngoscopy and tracheal intubation.
HUSSAIN  AM,  SULTAN  ST  (1999) concluded  that  bolus  injection  of 
fentanyl 2mcg/kg 2 minutes prior to laryngoscopy and intubation failed to protect 
against elevation of both the heart rate and systolic blood pressure, whereas esmolol 
at  2mg/kg provided consistent and reliable protection against the increase of heart 
rate but not arterial blood pressure.
MATERIALS AND METHODS
75  patients  of  ASA  physical  status  I  undergoing  elective  surgical 
procedure  under  General  Anaesthesia  with  endotracheal  intubation  were 
included in the study.
Patients  belonging  to  age  group  of  18-60  years  of  both  sexes  were 
included.
It  is  a  prospective  randomized  controlled  study.   The  study  was 
conducted after getting approval by our institution ethical committee and after 
obtaining written informed consent from the patient.   The surgeon was also 
duly informed of the study.
The study was done during the period from  January 07 to June 07 in the 
Department of Anaesthesia, Government Rajaji Hospital, Madurai.
Inclusion Criteria :
ASA  I  physical status
Patients with airway with modified mallampati Grade  I & II
Exclusion Criteria :
Patients with full stomach
Patients posted for emergency surgery
Patients with difficult airway
Hypertension, diabetes mellitus, Ischemic heart disease, pregnancy
Patients with contraindication to study drug
Patients refusal
Materials :
Inj.  Thiopentone 2.5%
Inj. Succinyl choline
Inj. Glycopyrrolate
Inj. Midazolam
Inj. Esmolol hydrochloride  
Inj. Fentanyl
Disposable 20 ml syringe
Laryngoscopy blade 3,4
Endotracheal tube of various sizes
Multichannel monitor
Monitors :
Non invasive automated blood pressure
ECG
Pulse oximetry
Methods :
Patients of both the sexes of ASA physical status I undergoing surgical 
procedure were randomly allocated into 3 groups.
Group C Control 10 ml of normal saline  
Group E Esmolol 2 mg / kg
Group F Fentanyl  3 mcg /kg
Preoperative preparations :
All the patients were admitted and they underwent routine investigations.
Hb %
Blood Sugar
Urea
Serum Creatinine
Electrolytes
X ray chest
ECG
Other investigations were obtained on the basis of the condition of the 
patient.
ANAESTHESIA PROTOCOL 
Preoperative  visit  was  done  to  allay  anxiety  and  good  rapport  was 
established with the patients.
All  the  patients  were  given  preoperative  night  sedation  with  tab. 
Diazepam 10 mg orally. 
Premedication :
All  patients  received  injection  Midazolam  0.05  mg/kg  and  Injection 
glycopyrrolate 0.2 mg intramuscularly 45 minutes before surgery.  Preoperative 
heart rate and blood pressure were recorded.
Induction :
Preoxygenation was done for 3 minutes. Base line heart rate and blood 
pressure were recorded.
This was followed by administration of normal saline 10ml in group C, 
Esmolol 2 mg/kg  in Group E  and Fentanyl 3 mcg/kg in Group F.  1 minute 
after the study drug all  patients were induced with thiopentone sodium in a 
dose of 5 mg/kg body weight followed by succinyl choline 1.5 mg / kg body 
weight.  Intubation was performed by the same person with the correct size 
cuffed endotracheal tube.
Maintenance :
Anaesthesia  was  maintained  with  controlled  ventilation  with  nitrous 
oxide 66% and oxygen 33%.   No surgical  stimulation  was permitted  for  7 
minutes after intubation.
Monitoring :
An assistant was assigned to check heart rate and systolic blood pressure, 
diastolic  blood  pressure  by  auscultation  at  the  time  of  preinduction,  after 
induction,  during laryngoscopy and intubation and thereafter  for  next  seven 
minutes at an interval of 1 minute. Results were tabulated.
Statistical Tools 
The information collected regarding all the selected cases were recorded in a 
Master  Chart.  Data  analysis  was  done  with  the  help  of  computer  using 
Epidemiological Information Package (EPI 2002).
Using this software, frequencies, percentage, range, mean, standard deviation, 
x2  and  'p'  values  were  calculated.  A 'p'  value  less  than 0.05 is  taken to  denote 
significant relationship.
OBSERVATION AND RESULTS
75  patients  under  this  study  were  categorized  into  3  groups.   They 
comprised both sexes with age ranging from 18-60 years.
1. Group C (Control)   :  consisting of  25  patients  who received 10 ml 
normal saline, 3 minutes prior to laryngoscopy.
2. Group E (Esmolol) : consisting of 25 patients who received 2 mg / kg, 3 
minutes prior to laryngoscopy.
3. Group F (Fentanyl) : consisting of 25 patients who received 3 mcg/kg, 3 
minutes prior to laryngoscopy.
RESULTS
Demographic profile of cases included in the study
Table 1 : Age
Age Group 
(in years)
Control 
Group
Esmolol 
Group
Fentanyl Group
Less than 20 - 2 4
20 – 29 5 7 8
30 – 39 11 8 7
40 – 49 7 5 4
50 & above 2 3 2
Total 25 25 25
Mean 36.2 34.5 31.5
S.D 8.2 12.0 10.8
‘P’ Significance 0.1605 (Not Significant)
There is no significant difference in the age composition of the cases in the 
three groups.
Table 2 : Sex
Sex Control Group Esmolol 
Group
Fentanyl 
Group
Males 13 (52%) 13 (52%) 14 (56%)
Females 12 (48%) 12 (48%) 11 (44%)
Total 25 (100%) 25 (100%) 25 (100%)
The sex composition of the three groups are nearly identical.
Table 3 : Weight
Weight in kgs Control Group Esmolol 
Group
Fentanyl 
Group
Mean 53.5 54.4 55.6
S.D 4.8 6.1 7.9
       ‘p’ 
Significance 
0.4186 
Not significant
The mean weight of the three groups does not difference significantly.
Heart  rate,  systolic  and  diastolic  blood  pressure  were  recorded  before 
induction, at the time of laryngoscopy and intubation and at 1 min interval for 7 min 
thereafter.
Table 4 : Basal Heart Rate, Systolic Blood Pressure, Diastolic blood pressure 
and Mean arterial Pressure
Basal Rates Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart Rate 81.9 + 12.9 86.9 + 10.8 87.4 + 11.9 0.0689 Not Significant
Systolic B.P 123.5 + 7.9 127.8 +  9.5 127 + 8.4 0.2289 Not Significant
Diastolic B.P 78.3 + 5.7 81 + 5.2 82.5 + 4.9 0.056 Not Significant
Mean arterial 
pressure
93.6 + 6.1 96.6 + 6.2 97.3 + 5.4 0.1033 Not Significant
Table shows the preoperative means heart rate, mean systolic mean diastolic 
blood pressure in groups C, E, F.
There is no statistical difference in the mean heart rate, mean systolic, mean 
diastolic blood pressure across 3 groups. ( p> 0.05).
Table  5  :  Heart  Rate,  Systolic  Blood Pressure,  Diastolic  blood pressure  and 
Mean arterial Pressure after induction
After 
inducti
on
Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart Rate 92.1 + 11.4 81 + 9.8 88.2 + 11.6 0.0025 Significant
Systolic B.P 123.6 + 8.9 117.1 + 11.2 118.4 + 10.9 0.0949 Not Significant
Diastolic B.P 79.3 + 5.7 76.6 + 5.7 76.2 + 6.0 0.1604 Not Significant
Mean arterial 
pressure
94 + 6.5 90 + 6.9 90.4 + 6.2 0.1311 Not Significant
Table  shows  the  mean  heart  rate,  mean  systolic  and  mean  diastolic  blood 
pressure after induction.  There is statistically significant difference in mean heart 
rate of patients across 3 groups (p< 0.01). The mean heart rate of esmolol group is 
lower than that of both the control and fentanyl group. 
There  is  no  statistical  difference  in  the  mean  systolic  and  diastolic  blood 
pressure among 3 groups.
Table  6  :  Heart  Rate,  Systolic  Blood Pressure,  Diastolic  blood pressure  and 
Mean arterial Pressure at laryngoscopy and endotracheal  intubation
At 
intub
ation
Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart
Rate
108.6 + 11.7 91 + 10.6 102.7 + 11.9 0.0001 Significant
Systolic 
B.P
152.1 + 8.6 139.6 + 7.2 142.8 + 12.1 0.0001 Significant
Diastolic 
B.P
95.2 + 6.5 88.6 + 6.0 94.6 + 11.1 0.0013 Significant
Mean 
arterial 
pressure
113.5 + 6.5 105. 7 + 5.5 110.6 + 10.7 0.0004 Significant
Table shows the mean heart rate, mean systolic and diastolic blood pressure at 
laryngscopy and endotracheal intubation.
There is high statistically significant difference in mean heart rate across the 3 
groups ( p < 0.001). The mean heart rate, blood pressure and mean arterial pressure 
of the esmolol group are the least. The difference with the control group and fentanyl 
group are statistically significant.
Table  7  :  Heart  Rate,  Systolic  Blood Pressure,  Diastolic  blood pressure  and 
Mean arterial Pressure at 1 minute
At 1 minute Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart Rate 110.6 + 11.6 92.4 +  10.8 103.5 +  12.5 0.0001 Significant
Systolic B.P 157.2 +  6.9 139.2 +  9.2 142.9 +  12.1 0.0001 Significant
Diastolic 
B.P
99.1 +  6.0 88.7 +  5.9 94.6 +  10.5 0.0001 Significant
Mean 
arterial 
pressure
118.6 +  5.4 105.6 +  5.9 110.6 +  10.3 0.0001 Significant
Table shows the mean heart rate, mean systolic and diastolic blood pressure at 
1 minute following  intubation.
There is statistically significant difference in mean heart rate of patients across 
3 groups ( p< 0.001). The heart rate are lowest in esmolol group followed by fentanyl 
group and then control group.
Mean systolic and diastolic pressure are having statistically significant among 
3 groups  (p< 0.01). The blood pressure and mean arterial pressure are lowest in the 
esmolol group followed by fentanyl and control group.
Table 8 :  Heart Rate, Systolic Blood Pressure,  Diastolic blood pressure and 
Mean arterial Pressure at 2 minutes
At 
2 minutes
Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart Rate 105.2 + 11.3 90.3 + 8.4 100.3 + 10.3 0.0001 Significant
Systolic B.P 150 + 8.5 133.5 + 7.5 139.5 + 11.2 0.0001 Significant
Diastolic 
B.P
95.5 + 6.6 84 + 5.1 90.8 + 11.2 0.0001 Significant
Mean 
arterial 
pressure
113.2 + 6.3 100.5 + 4.9 106.8 + 10.0 0.0001 Significant
Table shows the mean heart rate, mean systolic and diastolic blood pressure at 
2 minutes following intubation.
There  is  high  statistically  significant  difference  in  mean  heart  rate,  blood 
pressure and mean arterial pressure of patients across 3 groups ( p< 0.001).
Patients  is  esmolol  group  are  having  significantly  lower  values  than  the 
control and fentanyl group
Table 9 :  Heart Rate, Systolic Blood Pressure,  Diastolic blood pressure and 
Mean arterial Pressure at 5 minutes
At 5 
minute
Control 
Group
Esmolol 
Group
Fentanyl 
Group
‘p’ Significance
Heart Rate 93 + 11.2 86 + 8.4 91.7 + 9.5 0.034 Significant
Systolic B.P 130.7 + 7.9 121.3 + 10.0 127.7 + 6.7 0.0016 Significant
Diastolic 
B.P
81.8 + 4.7 78.2 + 5.4 81.6 + 6.2 0.0365 Significant
Mean 
arterial 
pressure
98.2 + 5.1 92.6 + 6.3 97 + 5.2 0.0015 Significant
Table shows the mean heart rate, mean systolic and diastolic blood pressure at 
5 minutes following intubation.
There  is  statistically  significant  difference  in  mean  heart  rate  of  the  three 
groups ( p< 0.001).
The  mean  systolic  diastolic  blood pressure  among  patients  in  esmolol  and 
fentanyl groups are significantly different from the control group.  
Table  10 
  CHANGES IN HEART RATE AT VARIOUS TIME INTERVALS
Heart rate 
at
Control 
Group
Esmolol 
Group
Fentanyl 
Group
Basal 81.9 + 12.9 86.9 + 10.8 87.4 + 11.9
At Study drug 89.2 + 11.9 87.2 + 10.5 90.8 + 14
After induction 92.1 + 11.4 81 + 9.8 88.2 + 11.6
At  laryngoscopy 
and intubation
108.6 + 11.6 91 + 10.6 102.7 + 11.9
1 Minute 110.6 + 11.6 92.4 + 10.8 103.5 + 12.5
2 minutes 105.2 + 11.4 90.3 + 8.4 100.3 + 10.3
3 minutes 100.9 + 9.9 88.6 + 9.2 96.8 + 9.4
4 minutes 98.7 + 10.3 86.5 + 8.9 93.5 + 8.9
5 minutes 93 + 11.2 86 + 8.4 91.7 + 9.5
7 minutes 81.7 +  12.9 86.9+ 10.9 87.7+  11.3
Table 11 
 SYSTOLIC BLOOD PRESSURE AT VARIOUS TIME INTERVALS
Systolic blood 
pressure at
Control 
Group
Esmolol 
Group
Fentanyl 
Group
Basal 123.5 + 7.9 127.8 + 9.5 127 + 8.4
At Study drug 124.2 + 9.8 125.2 + 11.4 126.2 + 10.1
After induction 123.6 + 8.9 117.1 + 11.2 118.4 + 10.9
At  laryngoscopy 
and Intubation
152.1 + 8.6 139.6 + 7.2 142.8 + 12.1
1 Minute 157.2 + 6.9 139.2 + 9.2 142.9 + 12.1
2 minutes 150 + 8.5 133.5 + 7.5 139.5 + 11.2
3 minutes 144.4 + 9.6 128.4 + 7.9 134.2 + 9.1
4 minutes 137.8 +  9 126.4 + 8.3 129 + 8.5
5 minutes 130.7 + 7.9 121.3 + 10 127.7 + 6.7
7 minutes 125.1+  6 128 +  8.2 126.8+  8.3
Table 12 
DIASTOLIC BLOOD PRESSURE AT VARIOUS TIME INTERVALS
Diastolic B.P at Control 
Group
Esmolol 
Group
Fentanyl 
Group
Basal 78.3 + 5.7 81 + 5.2 82.5 + 4.9
At Study drug 79.2 + 5 80.2 + 5.2 81.9 + 7
After induction 79.3 + 5.7 76.6 + 5.7 76.2 + 6
At laryngoscopy 
and Intubation
95.2 + 6.5 88.6 + 6 94.6 + 11.1
1 Minute 99.1 + 6 88.7 + 5.9 94.6 + 10.5
2 minutes 95.5 + 6.6 84 + 5.1 90.8 + 11.2
3 minutes 91.6 + 6.9 81.9 + 5.8 88 + 8.8
4 minutes 87.3 + 6.7 80.4 + 5.7 81.8 + 6.7
5 minutes 81.8 + 4.7 78.2 + 5.4 81.6 + 6.2
7 minutes 78.8+  4.4 79.6+  3.4 82.2+  4.5
 
Table 13
MEAN ARTERIAL PRESSURE AT VARIOUS TIME IN MINUTES
Mean arterial 
pressure at
Control 
Group
Esmolol 
Group
Fentanyl 
Group
Basal 93.6 + 6.1 96.6 + 6.2 97.3 + 5.4
At Study drug 94.4 + 6.1 95.2 + 6.9 97 + 6.9
After induction 94 + 6.5 90 + 6.9 90.4 + 6.2
At laryngoscopy 
and Intubation
113.5 + 6.5 105.7 + 5.5 110.6 + 10.7
1 Minute 118.6 + 5.4 105.6 + 5.9 110.6 + 10.3
2 minutes 113.2 + 6.3 100.5 + 4.9 106.8 + 10
3 minutes 109.6 + 7.3 97.3 + 5.7 102.8 + 8.2
4 minutes 104.3 + 7.1 95.8 + 6.1 97.6 + 4.6
5 minutes 98.2 + 5.1 92.6 + 6.3 97 + 5.2
7 minutes 94+  5.4 96.8+  5.3 97.6+  4.1
 
The peak increase in heart rate, Systolic blood pressure, diastolic blood 
pressure noticed during laryngoscopy and endotracheal  intubation in control 
group took 7 min to reach the preinduction value.
In fentanyl group,  mean heart  rate  took about  7 min to reach the pre 
induction value,  where  as  the  mean systolic,  diastolic  blood pressure   took 
about 4-5 minutes to reach the preinduction value.
In esmolol group. mean heart rate, mean systolic, diastolic blood pressure 
reached the pre induction values within 3 minutes.
DISCUSSION
Larngoscopy  and  endotracheal  intubation  frequently  induce  a 
cardiovascular stress response characterized by hypertension and tachycardia. This 
sympathoadrenal stress response to laryngoscopy results in an increase in myocardial 
O2 demand leading to ischemia and acute heart failure in susceptible individuals.
In view of  the frequent occurrence of hypertension and tachycardia during 
laryngoscopy even in normotensive individuals, it is perhaps rather surprising that 
complications have not  been met very often. One reason for this may be the transient 
nature  of  hypertension  which  usually  lasts  less  than  10  minutes.  It  is  possible 
however that some of the complications that occur during intubation or even later in 
the course of anaesthesia  may be precipitated by an episode of  hypertension and 
tachycardia,  following  endotracheal  intubation.  ELLIOF  (1980)  observed  left 
ventricular wall dysfunction following endotracheal intubation.
This  reflex  sympathetic  response  may  be  diminished  or  modified  locally, 
centrally and peripherally and attempts have been made to accomplish this using all 
these approaches with varying success.
In  an  attempt  to  blunt  these  potentially  adverse  haemodynamic  responses, 
different techniques and agents were used by many with varying success.
KING et al (1951) used ether, WYCOFF et al (1960) and J.KENNETH (1974) 
tried a combination of topical anaesthesia of larynx together with superior laryngeal 
nerve block to attenuate the stress response to endotracheal intubation.
STEINHAN and GASKIN (1963) used intravenous lignocaine, JAMES et al 
(1981) used lignocaine intratracheal spray, MASSON AND ECKANGOFF (1971) 
and  DENLINGER  J.K.  (1974)  and  STOELTING  (1978)  used  a  combination  of 
viscous lignocaine and topical intratracheal lignocaine and in 1979 LEAKO used a 
bolus of Sodium nitroprusside.
J.CURRAN et al (1980) tried droperidol, A.J.COLE and C.JORDAN (1980) 
and RICHARD et al (1981) studied the effect of β blockers using metaprolol and 
propranolol  respectively.  LUNN  (1979)   BENNET  and  STANLEY  (1980)  and 
DONAL  E.MARTIN  (1982)  studied  the  effect  of  fentanyl  in  attenuating  the 
intubation stress response.
Inhalation agents when used required deep levels and may delay recovery after 
short surgeries and can cause cardio vascular depression.
Adrenergic  blockers  are  effective  but  may  outlast  the  transient  intubation 
response and may cause profound hypotension and bradycardia. Sudden withdrawal 
results in rebound hypertension.
Use of Vasodilators like Sodium nitroprusside results in reflex tachycardia, 
lability in blood pressure, cerebral vasodilation with elevation of intracranial pressure 
and pulmonary venous admixture. 
Esmolol  an ultra-short acting cardioselective β blocker does not have these 
short comings.
The factors favouring its value in obtunding the responses to laryngoscopy and 
endotracheal intubation include (M.VUCEVIC et al  1992).
1. It  is  a  highly  cardioselective  agent  analogous  to  metaprolol  and  so  is 
unlikely to induce bronchospasm.
2. It has rapid distribution half-life of about 2 minutes and undergoes rapid 
esterase-mediated metabolism characterized by an elimination half-life of 
9.2 minutes and rapid offset of action.
3. No significant drug interaction.
So this study was done to compare the effects of single bolus  esmolol and 
fentanyl  versus  control  group  in  attenuating  the  haemodynamic  response  to 
intubation. 
Bolus  injection  of  esmolol  (2mg/kg)  given  3  minutes  prior  to  intubation 
provided  consistent  and  reliable  protection  against  increases  in  mean  heart  rate 
during laryngoscopy and endotracheal intubation and there after.
Bolus  injection of  fentanyl  (3 mcg/kg)  given 3 minutes  prior  to  intubation 
failed to attenuate the heart rate to the same extent as esmolol during laryngoscopy 
and endotracheal intubation and thereafter. At each level the difference in mean heart 
rate between esmolol group & fentanyl group is statistically insignificant compared 
to control group.  
Both esmolol and fentanyl are effective in protecting against increase in mean 
systolic blood pressure with no detectable difference between them at each level. 
This confers with the study of FENQ CK et al in 1996.
With esmolol, mean systolic and diastolic blood pressure returned to baseline 
value within 3minutes after intubation, whereas it was 5 minutes with fentanyl. This 
is in accordance with the study of M.HELFMMAN et al (1991).
Thus esmolol,  a  cardioselective β blocker would be useful  to attenuate the 
sympathoadrenal response accompanying laryngoscopy and endotracheal intubation.
SUMMARY 
This study is  done to compare the efficacy of  bolus injection of esmolol and 
fentanyl in attenuating the sympathoadrenal  response accompanying laryngoscopy 
and endotracheal intubation in 75 patients divided into 3 groups.
Group C -  Control 
Group E - Esmolol
Group F - Fentanyl
In control group, the mean basal heart rate was 81.9 beats / minute and reached 
maximum  of  110.6  beats/minute  at  1  minute  following  laryngoscopy  and 
endotracheal intubation and came back to the basal value of 81.7 beats/minute at 7 
minutes.
In esmolol  group, the mean basal heart rate was 86.9 beats / minute which 
reached  maximum of  92.4  beats/minute  at  1  minute  following laryngoscopy  and 
endotracheal intubation and came back to the basal value of 86.5 beats/minute at 4 
minutes following laryngoscopy and intubation.
In  fentanyl  group,  the  mean  basal  heart  rate  was  87.4  beats  /  minute  and 
reached maximum of 103.5 beats/minute at 1 minute following laryngoscopy and 
endotracheal intubation and came back to the basal value of 87.7 beats/minute at 7 
minutes following laryngoscopy and intubation.
In control  group,  the mean basal  systolic  and diastolic  blood pressure  was 
123.5mmHg and 78.3mmHg respectively and reached maximum of 157.2mmHg and 
99.1mmHg  respectively  at  1  minute  following  laryngoscopy  and  endotracheal 
intubation and came back to the basal value  at 7 minutes.
In esmolol  group, the mean basal  systolic and diastolic blood pressure was 
127.8mmHg and 81mmHg respectively and reached maximum value at  1  minute 
following  laryngoscopy  and  endotracheal  intubation  and  came  back  to  the  basal 
value  at 3 minutes following intubation.
In fentanyl group, the mean basal systolic and diastolic blood pressure was 
127mmHg and 82.5mmHg respectively and reached maximum value at  1  minute 
following  laryngoscopy  and  endotracheal  intubation  and  came  back  to  the  basal 
value  at 5 minutes following intubation.
It  was observed that bolus injection of esmolol  (  2mg/kg)  given 3 minutes 
prior to intubation provided consistent and reliable protection against increases in 
mean heart rate and mean systolic and diastolic blood pressure during laryngoscopy 
and endotracheal intubation and thereafter, compared to  control group and fentanyl 
group.
Whereas Fentanyl (3mcg/kg) 3 minutes prior to intubation failed to attenuate 
the raise in mean heart rate to the same extent as esmolol,  it attenuates the mean 
systolic, diastolic blood pressure to the same extent as compared to esmolol group. 
With  esmolol,  the  return  of  mean  systolic,  diastolic  blood  pressure  to 
preoperative value was relatively earlier when compared to fentanyl.
In this study, Esmolol and fentanyl both atteneuated the rise in blood pressure 
though  Esmolol  was  better.   Esmolol  attenuated  the  rise  in  heart  rate  with 
laryngoscopy and endotracheal intubation whereas fentanyl failed to protect against 
the rise in heart rate.
                             CONCLUSION
Bolus injection of fentanyl 3 mcg/kg 3 minutes prior to laryngoscopy and 
endotracheal intubation, attenuate the rise in blood pressure but failed to protect 
against the elevation of heart rate. 
Bolus injection of esmolol 2 mg/kg 3 minutes prior to laryngoscopy and 
endotracheal intubation, attenuates both rise in heart rate and blood pressure 
and reaches the basal value earlier than the fentanyl group.
Thus Esmolol, a cardioselective β blocker produces brief and predictive 
control over the pressor response (heart rate and blood pressure) attenuation 
when compared to fentanyl which causes the control of blood pressure during 
laryngoscopy and endotracheal intubation.
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PROFORMA
COMPARATIVE EVALUATION OF BOLUS ADMINISTRATION OF ESMOLOL 
AND FENTANYL FOR PRESSOR RESPONSE ATTENUATION DURING 
LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION
Name : Age : Sex  : Date :
Theatre :    Unit :        IP No.:    AssessNo.:
Address :
Diagnosis : Surgery  :
Anaesthesia  :
Pre anaesthetic Assessment :
Height PR CVS Airway
Weight BP RS ASA
Investigations :
Hb %
Urine Sugar
Albumin
Blood Sugar
Urea
Creatinine
Premedication :
Drug Dose Route Time
1.  Inj. Midazolam 0.05 mg / kg IM
2.  Inj. Glycopyrrolate 0.02 mg / kg IM
Study Drug :
Group :
Parameters Time PR per 
min
Systolic BP 
mm Hg
Diastolic BP 
mmHg
MAP mmHg
Basal
At study drug
After induction
At  laryngoscopy 
and intubation
1 min
2 min
3 min
4 min
5 min
7 min
Intra operative complications :
Recovery room condition :
Post operative visit   :
Characteristics of Beta Adrenergic Receptors
Receptor Agonists Tissue Responses Molecular 
mechanism
Beta 1 Iso > Epi = NE 
Dobutamine
a. Heart
b.Juxta 
glomerular 
cells
 Force and rate of 
contraction and AV 
nodal conduction 
velocity
Renin secretion
Activation of 
adenylcyclase 
and Calcium 
channels
Beta 2 Iso > Epi = NE 
Terbutaline
a. smooth 
muscles 
(vascular, 
bronchial, GIT 
and 
genitourinary)
b. Skeletal 
muscle
c. Liver
Relaxation
Glycogenolysis 
uptake of pottasium
Glycogenolysis 
gluconeogenesis
Activation of 
adenyl 
cyclase
Beta 3 Iso=NE>EPi Adipose tissue Lipolysis Activation  of 
adenyl cyclase
Iso  - Isoproterenol
Epi - Epinephrine
NE - Norepinephrine
Site of β 1 Receptors and responses of Effector organs to 
autonomic nerve impulses
Effector organs Receptor 
Type
Adrenergic responses Cholinergic responses
A. HEART
SA Node, Atria
AV Node
His-Purkinje system
Ventricle
β1
β1
β1
β1
     H.R.  ++
     Contractility and
Conduction velocity ++
    Automatically and 
conduction velocity ++
   Automatically and 
conduction velocity ++
    Contractility, conduction 
velocity, automaticity and 
rate of idioventricular pace 
makers +++
  H.R. Vagal arrest +++
   Contractility and  
  shortened AP duration ++
   Conduction velocity AV 
block +++
Little effect
B. RENAL 
ARTERIOLES
β1  +  β2   Constriction dilatation ++
C. INTESTINE
Motility and tone
β1  +  β2 Decrease Increase
D. KIDNEY
Renin secretion
α 1 +  β1 Decrease +
Increase ++
STRUCTURE OF ESMOLOL
CH3O2 CCH2 CH2           OCH2CHOHCH2HCH(CH3)2 HCL
STRUCTURE OF FENTANYL
